Financial Report

Interim consolidated income statement

1 January - 30 June (unaudited)

kEUR

Note

H1 2022

H1 2021

 

 

 

 

Revenue

4

133,656

135,136

Other operating income

 

954

2,936

Total income

 

134,610

138,072

 

 

 

 

Cost of sales

 

-96,776

-86,839

Gross profit

 

37,834

51,233

 

 

 

 

Marketing and sales expenses

 

-2,589

-2,133

Research expenses

 

-656

-696

General and administrative expenses

5

-19,107

-17,601

Total operating expenses

 

-22,352

-20,430

 

 

 

 

Operating result (EBIT)

 

15,482

30,803

 

 

 

 

Financial income

 

4

6

Financial expenses

 

-2,645

-1,282

Total financial result

 

-2,641

-1,276

 

 

 

 

Result before income taxes

 

12,841

29,527

 

 

 

 

Income tax charges

 

-2,594

-4,904

Result for the period

 

10,247

24,623

 

 

 

 

Attributable to shareholders of PolyPeptide Group AG

 

10,247

24,623

 

 

 

 

Earnings per share in EUR, basic

8

0.31

0.79

Earnings per share in EUR, diluted

8

0.31

0.79